Outcome following late marrow relapse in childhood acute lymphoblastic leukemia

Journal Article · Mon Oct 01 00:00:00 EDT 1984 · J. Clin. Oncol.; (United States)

OSTI ID:5615300

Chessells, J; Leiper, A; Rogers, D

Thirty-four children with acute lymphoblastic leukemia, who developed bone marrow relapse after treatment was electively stopped, received reinduction, consolidation, continuing therapy, and intrathecal (IT) methotrexate (MTX). Sixteen children who relapsed within six months of stopping treatment had a median second-remission duration of 26 weeks; all next relapses occurred in the bone marrow. In 18 children who relapsed later, the median duration of second remission was in excess of two years, but after a minimum of four years follow-up, 16 patients have so far relapsed again (six in the CNS). CNS relapse occurred as a next event in four of 17 children who received five IT MTX injections only and in two of 14 children who received additional regular IT MTX. Although children with late marrow relapses may achieve long second remissions, their long-term out-look is poor, and regular IT MTX does not afford adequate CNS prophylaxis. It remains to be seen whether more intensive chemotherapy, including high-dose chemoradiotherapy and bone marrow transplantation, will improve the prognosis in this group of patients.

• Research Organization: Hospital for Sick Children, London, England
• OSTI ID: 5615300
• Journal Information: J. Clin. Oncol.; (United States), Vol. 2:10
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
LEUKEMIA
CHEMOTHERAPY
RADIOTHERAPY
BONE MARROW
CENTRAL NERVOUS SYSTEM
CHILDREN
EVALUATION
METHOTREXATE
PATIENTS
TIME DEPENDENCE
AGE GROUPS
ANIMAL TISSUES
ANTIMETABOLITES
BODY
DISEASES
DRUGS
HEMATOPOIETIC SYSTEM
HEMIC DISEASES
MEDICINE
NEOPLASMS
NERVOUS SYSTEM
NUCLEAR MEDICINE
ORGANS
RADIOLOGY
THERAPY
TISSUES
550603* - Medicine- External Radiation in Therapy- (1980-)